Agenda at a Glance

Market Access Conference Day 2

Day 2: 7th February 2020

Pricing, Reimbursement And Patient Access

Dr. Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

    • New landscape for risk-sharing agreements among manufacturer, payer and patients
    • Understand the benefits of a good collaboration between payers and pharma companies to ensure patient access
    • What do the decision-makers on drug usage think today about how the industry is responding to the immense challenges it is facing?

Nazanin Mehin, Global Head, Value & Access, Diabetes & Cardiovascular, Sanofi

    • Advantages of market access teams in payer relationship
    • Payer evidence requirement in early development
    • How effective are the payer strategies in the current climate?
    • Best practices to obtain better pricing and reimbursement
    • Strategies to improve a better payer relationship

Nicki Catterick, Senior Director, Global Market Access and Pricing, Merck

10:45 am - Morning Break & Networking

 

Ryotaro Ishikawa Oka, Global Market Access Director, Novartis

    • Innovative approaches required to address the medicine access challenge
    • Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
    • The value of list prices against the backdrop of external price referencing and managed entry agreements.
    • Innovative policy options that needs to be developed, agreed upon and implemented.

Sandro Cesaro-Tadic, Head Global Pricing I8 & Product Pricing Strategies, F. Hoffmann-La Roche

  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship

Collaboration And Looking To The Future

    • Key trends driving increase in value communication
    • Target audiences who receive VC information
    • Types of VC tools used to achieve market access
    • Outsourcing of VC projects
    • Areas in need of improvement
    • Training needs in VC

Lucy Hoppe, Clinical Effectiveness Manager (Evidence Synthesis), Group Clinical, BUPA

  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Future trends and developments in the healthcare distribution

    • Understand the impact of RWE decisions on price and market access
    • The shift from RCT to RWE; closing the gap
    • RWE strategies

15:15 pm - Tea Break & Networking

  • Risk sharing agreements: incorporating financial models with performance based/outcome-based models
  • How to find the right partner?
  • In licensing and out licensing

  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • International Drug Price Indicator Guide WHO
  • Increasing collaboration between EU countries
  • Frontiers in Health Care
  • What will the future bring?

Panellist:

> Sandro Cesaro-Tadic, Head Global Pricing I8 & Product Pricing Strategies, F. Hoffmann-La Roche

 

Scroll to Top